Brief: Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08/11/2023 12:34
Nov 8 (Reuters) - HCW Biologics Inc HCWB.O :
* INVESTIGATOR SPONSOR OF HCW BIOLOGICS’ PHASE 1 CLINICAL
TRIAL
PRESENTED HUMAN DATA READOUT AND ANTI-CANCER MECHANISM OF ACTION
OF HCW9218 AT 38TH SITC ANNUAL MEETING
Source text for Eikon: ID:nGNX8KxPCM
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM